Corporate SPONSORS

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit our website and follow us on Twitter at @BeiGeneUSA.

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.

CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices.  CHOC's current preferred vendor is McKesson Specialty Health.

CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.

CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.

We’re proud to deliver breakthrough innovations in oncology that are helping to extend the lives of patients with certain types of cancer. We’re continuing to accelerate what we can achieve for the patients we serve, because everyone needs more ways to treat their cancer and, hopefully, more time. We’re working to invent a world where cancer isn’t just treated, but cured.

Founded in 1992 in Germany, MorphoSys is dedicated to making innovative biopharmaceuticals to help patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. MorphoSys is currently headquartered in Planegg, Germany. In 2019, the US head office was established in Boston

Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. With the acquisitions of Pharmacyclics in 2015 and Stemcentrx in 2016, our research and development efforts, and through collaborations, AbbVie's oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 200 clinical trials and more than 20 different tumor types. For more information, click here.

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. 

Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created Changing Tomorrow Day, an annual, worldwide volunteer event, to demonstrate this commitment.